Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generic Tazarotene Foam vs Fabior in Acne Vulgaris
NCT02267746Phase 3
Key facts
- Status
- Completed
- Start
- Jun 2014
- Primary completion
- Sep 2014
- Countries
- 2
- Sponsor
- Allergan
- Modality
- Orthosteric Ligands
- Drugs
- tazarotene
- Conditions
- acne vulgaris
01
Overview
Phase 3, randomised, double-blind trial of tazarotene in acne vulgaris (3 arms), sponsored by Allergan. Primary endpoints: Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts at 12 weeks and Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts at 12 weeks. Started Jun 2014; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Fabior™(tazarotene)
Reference listed drug: Fabior™ 0.1% foam
Tazarotene (Actavis)
Generic Tazarotene 0.1% foam
Vehicle foam
Placebo foam vehicle
03
Who it enrols
Patients aged 12-40 with acne vulgaris, having >=30 non-inflammatory and >=25 inflammatory lesions, and an IGA score of 3 or 4.
04
Endpoints
Primary
Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts
Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts
Secondary
Proportion of Subjects With an IGA Score That is at Least 2 Grades Less Than the Baseline Assessment
Beyond the preview
Go deeper on NCT02267746.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267746.